

## Curriculum Vitae **Akrit Sodhi, M.D., Ph.D.**

### DEMOGRAPHIC INFORMATION

#### Current Appointment:

Assistant Professor  
Wilmer Eye Institute, Department of Ophthalmology  
Johns Hopkins University School of Medicine  
Baltimore, MD  
07/10-present

Mailing Address:  
400 N. Broadway  
Smith Building, Room 4039  
Baltimore, MD 21231

(410) 614-4211 (Office)  
(410) 614-8577 (Fax)  
[asodhi1@jhmi.edu](mailto:asodhi1@jhmi.edu)

#### Education and Training (in chronological order):

Degrees/Year/Institution/Discipline

Undergraduate: **University of California at Los Angeles**  
Los Angeles, CA  
Degree: B.S. 1994  
Discipline: Microbiology and Molecular Genetics

Doctorate: **University of California at Davis**  
Davis, CA  
Degree: M.D. 2001  
Discipline: Medicine

Doctorate: **University of California at Davis**  
Davis, CA  
Degree: Ph.D. 2004  
Discipline: Comparative Pathology

Internship: **Johns Hopkins/Sinai Hospital of Baltimore**  
Baltimore, MD  
2004-2005  
Discipline: Internal medicine

Residency: **Wilmer Eye Institute, Johns Hopkins School of Medicine**  
Baltimore, MD  
2005-2008  
Discipline: Ophthalmology

Fellowship: **Wilmer Eye Institute, Johns Hopkins School of Medicine**  
Baltimore, MD  
2008-2010  
Discipline: Vitreoretinal Surgery

**Professional Experience** (in chronological order):

Positions/Institutions/Dates

- 7/09-6/10      Assistant Chief of Service  
General Eye Service, Wilmer Eye Institute  
Johns Hopkins School of Medicine  
Baltimore, MD
- 7/09-6/10      Associate Director of Ocular Trauma  
Wilmer Eye Institute  
Johns Hopkins School of Medicine  
Baltimore, MD
- 07/10-present Assistant Professor  
Retina Division, Wilmer Eye Institute  
Johns Hopkins School of Medicine  
Baltimore, MD

**RESEARCH ACTIVITIES**

**Publications**

Peer-reviewed scientific articles

1.      **Sodhi, A.**, Montaner, S., Patel, V., Zohar, M., Bais, C., Mesri, E., and Gutkind, J.S. The Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor Upregulates VEGF Expression and Secretion through Multiple Signaling Pathways Acting on Hypoxia Inducible Factor-1alpha. *Cancer Research*, 2000:60:4873-80
2.      Montaner, S., **Sodhi, A.**, Pece, S., Mesri, E., and Gutkind, J.S. The Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor Induces Endothelial Cell Survival through the Activation of Akt/PKB. *Cancer Research*, 2001:61:2641-48.
3.      **Sodhi, A.**, Montaner, S., Miyazaki, H., and Gutkind, J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1 alpha in rasV12 stimulation of VEGF. *Biochemical and Biophysical Research Communications*, 2000:287: 292-300.
4.      \*Montaner, S., \***Sodhi, A.**, Molinolo, A., Bugge, T.H., Sawai, E.T., He, Y., Li, Y., Ray, P., and Gutkind, J.S. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell*, 2003:3:23-36.  
\*equal contribution.
5.      Servitja, J.M., Marinissen, M.J., **Sodhi, A.**, Bustelo, X.R., and Gutkind, J.S. Rac1 function is required for Src-induced transformation: Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. *The Journal of Biological Chemistry*, 2003:278:34339-46.
6.      **Sodhi, A.**, Montaner, S., Román, J., Li, Y., Sawai, E.T., and Gutkind, J.S. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. *Proceedings of the National Academy of Science, U S A*, 2004:14:4821-26.

7. Montaner, S., **Sodhi, A.**, Servitja, J.M., Ramsdell, A.R., Barac, A., Sawai, E.T., and Gutkind, J.S. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. *Blood*, 2004;9:2903-11.
8. Amornphimoltham P., Patel V., **Sodhi A.**, Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., and Gutkind J.S. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Research*, 2005;65:9953-61
9. Montaner S., **Sodhi A.**, Ramsdell A.K., Martin D., Hu J., Sawai E.T., and Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. *Cancer Research*, 2006;66:168-74.
10. **Sodhi, A.**, Chaisuparat, R., Hu, J., Ramsdell, R.K., Manning, R.D., Sausville, E.A, Sawai, E.T., Molinolo, A.A., Gutkind, J.S., and Montaner, S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor. *Cancer Cell*, 2006: 10: 133-143.
11. Ma, T., Jham, B.C., Hu, J., Friedman, E.R., Basile, J.R., Molinolo, A., **Sodhi, A.**, and Montaner, S. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. *Proceedings of the National Academy of Science, U S A*, 2010: 32: 14363-68
12. Jham, B.C., Ma, T., Hu, J., Chaisuparat, R., Friedman, E.R., Pandolfi, P.P., Schneider, A., **Sodhi, A.**, and Montaner, S. Amplification of the Angiogenic Signal through the Activation of the TSC/mTOR/HIF Axis by the KSHV vGPCR in Kaposi's Sarcoma. *PLoS ONE*, 2011: 6: e19103.
13. Rodrigues, M., Xin, X., Jee, K., Kashiwabuchi, F., Ma, T., Babapoor-Farrokhran, S. Bhutto, I., Daoud, Y., Baranano, D., Solomon, S., Luty, G., Semenza, G.L., Montaner, S., and **Sodhi, A.** VEGF Secreted by Hypoxic Müller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy. *Diabetes*. 2013: (available online July 24, 2013).
14. Rodrigues, M., Iliff, N.T., Eberhart, C.G., Montaner, S., and **Sodhi, A.** Scleral Penetration of an Unusually Aggressive Case of a Retinal Hemangioblastoma. *Canadian Journal of Ophthalmology*. 2013: 48(4):e80-2
15. Hsu, A.W., **\*Sodhi, A.**, Eberhart, C.G., and Goldberg, M.F. Regression of Choroidal Neovascularization in Response to Systemic Chemotherapy for Cancer. *Canadian Journal of Ophthalmology*. August, 2013: 48(4):e80-2.  
\*corresponding author
16. Xin, X., Rodrigues, M., Umapathi, M.D., Kashiwabuchi, F., Ma, T., Wang, S., Hu, J., Bhutto, I., Welsbie, D., Duh, E., Handa, J.T., Eberhart, C.G., Luty, G., Semenza, G.L., Montaner, S., and **Sodhi, A.** Hypoxic Retinal Müller Cells Promote Diabetic Macular Edema by HIF-1-Dependent Upregulation of Angiopoietin-like 4. *Proceedings of the National Academy of Science, U S A*. 2013: (available online August 19, 2013).

### Review Articles

1. **Sodhi, A.**, S. Montaner, and Gutkind, J.S. Viral hijacking of G-protein-coupled-receptor signalling networks. *Nature Reviews Molecular and Cellular Biology*, 2004:1:998-1012.
2. **Sodhi, A.**, S. Montaner, and Gutkind, J.S. Does Dysregulation of a Deregulated Viral GPCR Trigger Kaposi's Sarcomagenesis? *The FASEB Journal*, 2004:3:422-27
3. **Sodhi, A.**, Leung, L.S., Do, D.V., West, E.S., Schein, O.D., and Handa, J.T. Recent Trends in the Management of Rhegmatogenous Retinal Detachment. *Survey of Ophthalmology*, 2008: 53:50-67.
4. Whitcup, S.M., **Sodhi, A.**, Atkinson, J., Holers, M., Sinha, D., and Dick, A.D. The Role of the Immune Response in Age-Related Macular Degeneration. *International Journal of Inflammation*. 2013: (available online May 23, 2013).
5. Krispel, C., Rodrigues, M., Xin, X., and **Sodhi, A.** Ranibizumab in Diabetic Macular Edema. *World Journal of Diabetes*. 2013 (in press).

#### Book Chapters

1. **Sodhi A.**, Montaner S, and Gutkind, J.S. Molecular mechanisms of cancer. In: Finkel T, Gutkind J.S., eds. *Signal Transduction and Human Disease*. Hoboken, NJ: John Wiley & Sons, 2003;71-142.
2. **Sodhi, A.** and Merbs, S. Molecular Genetics of Choroidal Melanoma and its relevance to Clinical Practice. In Ryan, S.J., ed. *Retina, Fifth Edition*. Philadelphia, PA: Elsevier/Mosby, 2012: Chapter 141.

#### Other Media

None

Inventions, Patents, Copyrights (pending, awarded):

Treatment of Ischemic Retinopathies (patent pending).

Modified Anthrax Toxin Selectively Targets Activated Endothelial Cells: A Novel Therapeutic Approach for the Treatment of Retinal Neovascular Disease (provisional patent).

**Extramural Sponsorship** (current, pending, previous):

#### Current

1K08EY021189-01 (PI)

04/01/11-03/31/16

NIH/NEI

"HIF dysregulation as a novel genetic model to study retinal neovascular disease."

The major goal of this project is to examine the contribution of genes upregulated by Hypoxia Inducible Factor (HIF) to the breakdown of endothelial tight junctions (inner blood retinal barrier) in VHL hemangioblastomas.

Role: PI; % effort: 9.6 cal mo (80%)

Current Year: \$166,725; total direct: 179,577

RPB Career Development Award (PI) 1/1/11-12/31/15  
Research to Prevent Blindness Foundation  
“Hypoxia inducible factor (HIF) upregulation and gene dysregulation in retinal and choroidal neovascular disease.”  
The major goal of this project is to examine the contribution of genes upregulated by Hypoxia Inducible Factor (HIF) to the breakdown of endothelial tight junctions (inner blood retinal barrier) in retinal/choroidal neovascular disease.  
Role: PI; % effort: 0.6 cal mo (5%)  
Current Year: \$50,000; total direct: \$200,000

William and Ella Owens Medical Research Foundation Grant (PI) 1/1/13-12/31/13  
William and Ella Owens Medical Research Foundation  
“Examination of the Role of HIF Up-regulation of ANGPTL4 in the Promotion of Vascular Permeability and Macular Edema in Patients with Ischemic Retinopathies”  
The major goal of this project is to determine the relative contribution of HIF and ANGPTL4 to the promotion of vascular permeability in patients with ischemic retinopathies.  
Role: PI; % effort: 0.6 cal mo (5%)  
Current Year: \$40,000; total direct: \$40,000

### Previous

ASCRS Foundation Research Grant (PI) 4/1/12-3/31/13  
American Society of Cornea and Refractive Surgery  
“Modified Anthrax Toxin Engineered to Selectively Target MMP-Expressing Activated Endothelial Cells as a Novel Therapeutic Approach for the Treatment of Corneal Neovascular Disease”  
The major goal of this project is to determine whether bacterial toxins engineered to be active only in the presence of matrix metalloproteases can selectively kill “activated” endothelial cells in corneal neovascular disease.  
Role: PI; % effort: 0.6 cal mo (5%)

K12- EY015025 Institutional Grant (H.A. Quigley, PI) 07/01/10-03/31/11  
NIH/NEI  
“VHL hemangioblastomas as a novel genetic model of Hypoxia inducible factor (HIF) dysregulation to study the early molecular events characterizing break down of the inner blood retinal barrier.”  
The major goal of this project was to examine the contribution of genes upregulated by Hypoxia Inducible Factor (HIF) to the breakdown of endothelial tight junctions (inner blood retinal barrier) in VHL hemangioblastomas.  
Role: K12 award recipient; % effort 10.8 ca mo (90%)

VHL Family Alliance Research Grant (James T. Handa, PI) 07/1/08-06/30/09  
VHL Family Alliance  
“Use of a novel genetic animal model to study the molecular pathogenesis of retinal hemangioblastomas in VHL disease.”  
The major goal of this project was to develop an animal model which reproduces the loss of pVHL expression in the retina.  
Role: Co-PI; % effort 0 ca mo (0%)

### **Clinical Trials**

Principal Investigator for Trials on Age-related Macular Degeneration

1. Protein Analysis of Ocular Anterior Chamber Fluid and Blood Serum from Patients with neovascular Age-Related Macular Degeneration.

Investigator for Trials on Age-related Macular Degeneration

1. A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat®, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients with Advanced Neovascular Age-Related Macular Degeneration.
2. A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients with Age-Related Macular Degeneration.
3. Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device.
4. Longitudinal Evaluation of Geographic Atrophy Using Novel Imaging Modalities.
5. Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device.
6. Protocol CFD4870G: A Phase IB/II, M, Randomized, Single-masked, Sham Injection-controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every-other-month to Patients with GA.

Investigator for Trials on Vein Occlusions

1. Ranibizumab Dose Comparison (0.5mg and 2.0mg) and the Role of Laser in the Management of Retinal Vein Occlusion – A Pharmacodynamic Approach (RELATE).

Principal Investigator for Trials on Diabetic Macular Edema, and Diabetic Retinopathy

1. Protein Analysis of Ocular Anterior Chamber Fluid and Blood Serum from Patients with and without Diabetic Retinopathy.
2. Protein Analysis of Ocular Anterior Chamber Fluid and Blood Serum from Patients with and without Diabetic Macular Edema

Investigator for Trials on Diabetic Macular Edema, and Diabetic Retinopathy

1. Ranibizumab for Edema of the macula in Diabetes: Protocol 3 with High Dose – the READ 3 Study.
2. Phase 1b/2a Open-Label, Multiple Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema
3. iDEAL Study: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic.

Principal Investigator for Other Clinical Trials

1. Examination of Anterior Segment Lesions in Autopsy and Enucleated Human Eyes.

Investigator for Other Clinical Trials

1. A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human

- Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis (M11-327)
2. A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects requiring High-Dose Corticosteroids for Active Non-Infectious Intermediate-, Posterior-, or Pan-uveitis.
  3. A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis.
  4. A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye.

#### Contracts

None

#### Other

None

### **EDUCATIONAL ACTIVITIES**

#### **Teaching:**

##### Classroom Instruction (course title, dates, role)

1. Wilmer Ophthalmology Residents Lecture Series. Retinal Detachment and Proliferative Vitreoretinopathy. Wilmer Eye Institute, Johns Hopkins School of Medicine. Annual Lecture. 2010-2011.
2. Wilmer Ophthalmology Residents Lecture Series. Pseudophakic Cystoid Macular Edema. Wilmer Eye Institute, Johns Hopkins School of Medicine. Annual Lecture. 2010-2011.
3. Hopkins Howard Hughes Lecture Series. Choosing a Career as a Physician-Scientist. Johns Hopkins School of Medicine. December 13, 2010.
4. Wilmer Ophthalmology Residents Lecture Series. Retina Emergencies. Wilmer Eye Institute, Johns Hopkins School of Medicine. Annual Lecture. 2012-present.

##### Clinical instruction (service, dates, role)

1. Education Champion, Retina Division, Department of Ophthalmology, Wilmer Eye Institute, 2012-present. Role: Organize Retina Residents' clinical and surgical training, and the Retina lecture series; supervise the Resident Retina clinics).
2. Retina Division, Department of Ophthalmology, Wilmer Eye Institute, 2010-present. Role: Supervise and teach Medical Students, Ophthalmology Residents, Vitreoretinal Fellows in clinic, operating room, and formal lecture series.
2. Retina Division Weekly Teaching Conference, Wilmer Eye Institute, 2010-present. Role: Discuss complex vitreoretinal medical and surgical cases at a weekly conference with Ophthalmology Residents and Vitreoretinal Fellows.

##### CME instruction (Course title, dates, role)

1. Retinal Anatomy and Physiology, Including Photochemistry. 15<sup>th</sup> Annual Wilmer Technician Course. Johns Hopkins School of Medicine, Baltimore, MD. March 27, 2010.
2. Uveal Melanoma: Current Therapies and Emerging Targets. 23<sup>rd</sup> Annual Current Concepts in Ophthalmology. Johns Hopkins School of Medicine, Baltimore, MD. December 3, 2010.
3. Management of Capillary Non-Perfusion and Neovascularization Following Retina Vein Occlusion. What's New in Diabetic Retinopathy and Venous Occlusive Disease. Johns Hopkins School of Medicine, Baltimore, MD. December 11, 2010.
4. Discussant. Wilmer Resident Association. Johns Hopkins School of Medicine, Baltimore, MD. June 3, 2011.
5. Case Presentations. 41<sup>st</sup> Anniversary Wilmer Retina Division/New Horizons in Retina. Victor, Idaho. June 30, 2011.
6. Management of Capillary Non-Perfusion and Neovascularization Following Retina Vein Occlusion. What's New in Diabetic Retinopathy and Venous Occlusive Disease. Johns Hopkins School of Medicine, Baltimore, MD. November 11, 2011.
7. Case Presentations. What's New in Diabetic Retinopathy and Venous Occlusive Disease. Johns Hopkins School of Medicine, Baltimore, MD. November 11, 2011.
8. Discussant. Wilmer Resident Association. Johns Hopkins School of Medicine, Baltimore, MD. June 8, 2012.
9. Case Presentations. Age-Related Macular Degeneration in 2012: The Paradigm Continues to Evolve. Johns Hopkins School of Medicine, Baltimore, MD. June 9, 2012.
10. Management of Capillary Non-Perfusion and Neovascularization Following Retina Vein Occlusion. What's New in Diabetic Retinopathy and Venous Occlusive Disease. Johns Hopkins School of Medicine, Baltimore, MD. October 12, 2012.
11. Vein Occlusion Case Presentations (Panel member). What's New in Diabetic Retinopathy and Venous Occlusive Disease. Johns Hopkins School of Medicine, Baltimore, MD. November 11, 2012.
12. Imaging in Retinal Disease. What's a Retina Specialist to do? Macular 2013. Johns Hopkins School of Medicine, Baltimore, MD. January 19, 2013.
13. Identification of New Therapeutic Targets for the Treatment of Diabetic Eye Disease? 30th Annual Wilmer Nursing Conference. Johns Hopkins School of Medicine, Baltimore, MD. June 14, 2013.

**Mentoring (pre- and post-doctoral):**

Advisees (provide: name, dates, degree, present position, awards/grants/degrees received under your direction.)

Pre-doctoral Advisees

1. Annie Hsu 2010. Johns Hopkins School of Medicine.
2. Kathy Jee 2012-present. Johns Hopkins School of Medicine.
3. Rakesh Chopde 2012. University of Maryland.
4. Syed Juaid Hassan 2012-present. University of Maryland.
5. Brooks Puchner 2013-present. Johns Hopkins School of Medicine.

Post-doctoral advisees

Ophthalmology Residents:



1. Derek Welsbie, MD, PhD 2009-2010. Current position: Assistant Professor, Wilmer Eye Institute, Johns Hopkins School of Medicine.
2. Ala Moshiri, MD, PhD. 2009-2010. Current position: Vitreoretinal Surgical Fellow, Wilmer Eye Institute, Johns Hopkins School of Medicine.
3. Adam Wenick, MD, PhD. 2009-2010. Current position: Vitreoretinal Surgical Fellow, Wilmer Eye Institute, Johns Hopkins School of Medicine.
4. Shameema Sikder, M.D. 2009-2010. Current position: Assistant Chief of Service, Wilmer Eye Institute, Johns Hopkins School of Medicine.
5. Houman Hemmati, MD, PhD. Current position: Cornea Fellow, Massachusetts Eye and Ear Infirmary, Harvard School of Medicine.
6. Esther Chang, MD. 2009-2010. Current position: Virginia Eye Consultants
7. Ilya Leyngold, MD. 2009-2010. Current position: Oculoplastics Fellow, Center for Facial Appearances, Utah.
8. Bryn Burkholder, MD. 2009-2011. Current position: Assistant Professor, Wilmer Eye Institute, Johns Hopkins School of Medicine.
9. Nhuyen Khoi Ha, MD. 2009-2011. Current position: Vitreoretinal Surgical Fellow, Wilmer Eye Institute, Johns Hopkins School of Medicine.
10. Bryan S. Lee, MD, JD. 2009-2011. Current position: Cornea Fellow, Moran Eye Center, The University of Utah.
11. Sophie Liao, MD. 2009-2011. Current position: Oculoplastics Fellow, Bascom Palmer Eye Institute, University of Miami.
12. Allison McCoy, MD, PhD. 2009-2011. Current position: Oculoplastics Fellow, Kellogg Eye Institute, University of Michigan.
13. Daniel Paskowitz, MD, PhD. 2009-2011. Current position: Cornea Specialist. Private practice.
14. Fasika Woreta, MD, MPH. 2009-2011. Current position: International Fellow, Wilmer Eye Institute.
15. J. Peter Campbell, MD, MPH. 2009-2012. Current position: Retina Fellow, Casey Eye Institute, Oregon Health Sciences.
16. Connie Chen, MD. 2009-2012. Current position: Retina Fellow, Wilmer Eye Institute, Johns Hopkins School of Medicine.
17. Libby Houle, MD. 2009-2012. Current position: Oculoplastics Specialist. Private Practice.
18. Christina Moon, MD. 2009-2012. Current position: Cornea Fellow, Bascom Palmer Eye Institute, University of Miami.
19. Afshan Nanji, MD, MPH. 2009-2012. Current position: Cornea Fellow, Bascom Palmer Eye Institute, University of Miami.
20. David Ramsey, MD, PhD, MPH. 2009-2012. Retina Fellow, Massachusetts Eye and Ear Infirmary, Harvard School of Medicine.
21. Chrisina Weng, MD, MBA. 2009-2012. Retina Fellow, Bascom Palmer Eye Institute, University of Miami.
22. Sumayya Ahmad, MD. 2012-present.
23. Jessica Chang, MD. 2012-present.
24. Roomasa Channa, MD. 2012-present.
25. Farhan Merali, MD. 2012-present.
26. Uma Sachdeva, MD, PhD. 2012-present.
27. Aaron Wang, MD, PhD. 2012-present.
28. Meraf Wolle, MD, MPH. 2012-present.
29. Tin Yan Liu, MD. 2013-present.
30. Sherveen Salek, MD. 2013-present.
31. Craig See, MD. 2013-present.
32. Sonya Thomas, MD. 2013-present.

33. Guadalupe Villarreal, MD. 2013-present.

**Vitreoretinal Surgical Fellows:**

1. Thomas Lee, MD. 2010-2011. Current position: Buski Eye Center, Edmonton, Alberta, Canada.
2. Shiri Zayit-Soudry, MD. 2010-2011. Current position: Research Fellow, University of California at San Francisco.
3. Muge Kesen, MD. 2010-2011. Current position: Assistant Professor, West Virginia University.
4. Adam Wenick, MD, PhD. 2010-2012. Current position: Assistant Professor, Wilmer Eye Institute, Johns Hopkins School of Medicine.
5. Ala Moshiri, MD, PhD. 2010-2012. Current position: Assistant Professor, University of California at Davis.
6. Alex Leder, MD. 2010-2012. Current position: Assistant Professor, Albert Einstein Medical College.
7. Nhuyen Khoi Ha, MD. 2011-2013. Current position: Vitreoretinal Surgeon, Florence, SC.
8. Claudia Krispel, MD, PhD. 2011-2013. Current position: Vitreoretinal Surgeon, Las Vegas, NV.
9. Connie Chen, MD. 2012-present.
10. S. Mahmood Ali Shah, MD. 2012-present.
11. Ian Han, MD. 2013-present
12. Yannis Paulus, MD. 2013-present

**Research Fellows:**

1. Priya Umapathi, MD. 2010-2011. Current Position: Internal Medicine Residency, UMDNJ.
2. Murilo Rodrigues, MD. 2011-2012. Current Position:
3. Fabiana Kashiwabuchi, MD. 2011-2012
4. Xiaoban Xin, PhD, 2011-present
5. Savalan Babapoor-Farrokhran, 2012-present

**Oral Qualifying Exam committees:**

1. Samantha Semenko, Pathobiology Graduate Program, Johns Hopkins School of Medicine, Baltimore, MD, 2011.
2. Allison Hanaford, Pathobiology Graduate Program, Johns Hopkins School of Medicine, Baltimore, MD, 2012.

**Thesis committees:**

None

**Training grant participation**

None

**Editorial Activities:**

Associate Editor appointments

None

Editorial Board appointments

None

Journal peer review activities:

Ad-hoc Peer reviewer Ophthalmology, Invest Ophthalmol Vis Sci., for Exp Eye Res, Free Radical Biology and Medicine, Cancer Research, Journal of Biological Chemistry.

Book reviewer:

None

**CLINICAL ACTIVITIES:**

**Certification:**

NPI: 1578609962

Tax ID#: 520595110

Medical, other state/government licensure (date, identification #)

DEA Registration Certificate: Identification #: FS0907723.

Maryland. Identification #: D0067740.

Maryland Controlled Substances license. Identification #: M65954

Boards, other specialty certification (date, identification #):

National Board of Medical Examiners Certification: September, 2009, #29662.

American Board of Ophthalmology, 2011. Fellow.

**Service Responsibilities (specialty-role, time commitment):**

Specialty: Vitreoretinal Diseases. Role: Medical and surgical treatment of vitreoretinal diseases. Time commitment: 20%.

**ORGANIZATIONAL ACTIVITIES**

**Institutional Administrative Appointments (committees, dates):**

Admissions Committee interviewer, NIH-Howard Hughes Medical Institute Research Scholars Program (NIH-HHMI), 2003-2004.

Member, Johns Hopkins/Wilmer Eye Institute Emergency Room Transition Committee, 2009-2010.

Member, Wilmer Ophthalmology Residency Selection Committee, 2010-present

Member, Bayview Comprehensive Ophthalmology Search Committee, 2010-2011.

Member, General Eye Service Search Committee, 2010-2011.

Member, Retina Division Faculty Search Committee, 2011-2012.

Member, Glaucoma Division Faculty Search Committee, 2012-present.

Member, Ocular Oncology Faculty Search Committee, 2012-present.

**Professional Societies (membership, committees, dates, role):**

American Academy of Ophthalmology - 2010-present. Role: Fellow.  
Association for Research in Vision and Ophthalmology – 2010-present. Role: Member.  
Maryland Society of Eye Surgeons and Physicians - 2012-present. Role: Member.  
American Society of Retina Specialists – 2012-present. Role: Member.

**Conference Organizer, Session Chair (sponsor, date, role):**

5Th Workshop on the TVA-based Gene Delivery System, Bethesda, MD, April 24, 2004.  
Organizer.

**Advisory Committees, Review Groups (sponsor, date, role):**

Expert Legal Witness. 2010-present. Role: Consultant for Vitreoretinal Diseases and Ocular Trauma cases.  
Expert Opinion. District of Connecticut. U.S. Attorney's Office. 2011-2012. Role: Consultant for Vitreoretinal Diseases.  
Fifth annual conference of the Arnold and Mabel Beckman Initiative for Macular Research. January 24-26, 2013. Role: Invited member.

**Consultantships (organization/agency, date, role):**

None

**RECOGNITION**

**Awards, honors (title, date, description, sponsor):**

1990-1994	Regent's Scholar – UCLA
1991	Golden Key Honor Society – UCLA
1994	Honors thesis – UCLA
1994	Phi Beta Kappa – UCLA
1994	Graduated Summa Cum Laude – UCLA
1997	Morton Leavitt Research Scholarship – UC Davis School of Medicine
1997	UC Davis Pre-doctoral Research Fellowship – UC Davis School of Medicine
1997-1999	HHMI/NIH Research Scholar – HHMI and the NIH
1999-2001	HHMI Research Scholar's Award – HHMI (full scholarship for medical school)
2001-2003	NIH AIDS Research LRP Award – National Institutes of Health
2003	Fellows Award for Research Excellence – National Institutes of Health
2003	Special Act Award – US Human Health Services, National Institutes of Health, "For initiative and leadership in the establishment of an AIDS-Malignancies program at the Oral and Pharyngeal Cancer Branch."
2005-2006	Morton Goldberg Research Grant Award – Wilmer Eye Institute, JHMI
2006	Mitchell Prize for Resident Research – Wilmer Eye Institute, JHMI
2008	Mitchell Prize for Resident Research – Wilmer Eye Institute, JHMI
2008-2010	Mary Hutchinson Endowed Vitreoretinal Fellowship – Wilmer Eye Institute, JHMI
2008-2009	Heed Fellow – Heed Ophthalmic Foundation
2008	Heed Fellows' Fellow – Heed Ophthalmic Foundation
2009	Wilmer Teaching Award, Fellow – Wilmer Eye Institute, JHMI

2011-2015 RPB Career Development Award  
Research to Prevent Blindness  
2011-2012 Stephen J. Ryan, Jr., M.D. Scholar – Wilmer Eye Institute, JHMI  
2013 Most Promising Assistant Professor Award – Wilmer Eye Institute, JHMI

**Invited Talks, Panels (title, date, venue, sponsor):**

1. Hypoxic Dysregulation in Retinal Neovascular Disease. Invited Lecture at Kellogg Eye Institute, University of Michigan. Ann Arbor, MI. October 19, 2009.
2. HIF – The Good, The Bad, and The Ugly. Wilmer Eye Institute. Friday Afternoon Meeting Lecture Series. Baltimore, MD. May 17, 2011.
3. The Immune System in Age Related Macular Degeneration. Invited Lecture. Fifth annual conference of the Arnold and Mabel Beckman Initiative for Macular Research. Irvine, CA. January 26, 2013.
4. Identification of Novel Therapeutic Targets for the Treatment of Diabetic Eye Disease. Wilmer Eye Institute. Friday Afternoon Meeting Lecture Series. Baltimore, MD. May 14, 2013

**OTHER PROFESSIONAL ACCOMPLISHMENTS**

None

Last revised: 8/21/13